Lake Street analyst Brooks O’Neil raised the firm’s price target on Tandem Diabetes to $75 from $60 and keeps a Buy rating on the shares. The firm sees “many reasons for optimism for 2024 and beyond” as it argues that innovation drives growth in diabetes management, growth drives multiple expansion in the stock market, and that “the engines are revving at Tandem and the light is green.” The firm anticipates “both unexpectedly strong growth and multiple expansion for Tandem this year,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem mobile app ‘recall’ a ‘non-event,’ says Stifel
- FDA announces Tandem Diabetes recall of t:connect mobile app
- Tandem Diabetes price target raised to $55 from $39 at Barclays
- Tandem Diabetes price target raised to $50 from $35 at Piper Sandler
- Tandem Diabetes price target raised to $50 from $45 at Wells Fargo